CEACAM5 and neoplasm: The test analyzes over 1000 genomic regions and more than 2000 methylation sites, as well as protein biomarkers such as carcinoembryonic antigen (CEA), to achieve high sensitivity and specificity for detecting MRD and predicting recurrence in CRC patients without prior knowledge of tumor genomics [34].